Akebia crashes on vadadustat flop in larger anemia indication. Will AZ, FibroGen own the market?

What was previously expected to be a three-way battle in the novel HIF-PHI renal anemia drug class now has one man down. Akebia Therapeutics has posted a surprise trial flop, which one analyst said could hand the rival FibroGen-AstraZeneca team an early monopoly of the market. On Thursday, Akebia said its Otsuka-partnered vadadustat was linked to… Read More »

Restore and revive healthy-looking nails with these top fungal treatments

Okay, it might not be the sexiest of topics, but fungal nail infections are very common, affecting 48% of people up to the age of 70. The best fungal nail treatments will work to return discoloured nails to their healthy-looking best. Fungal nail infections usually affect your toenails but can sometimes occur on fingers. They… Read More »

AstraZeneca begins final trials of Oxford University coronavirus vaccine enrolling 50,000 people

AstraZeneca begins final trials of Oxford University coronavirus vaccine enrolling 50,000 people worldwide and 30,000 in the US as company signs £15million manufacturing deal Thousands volunteers already being injected with jab in UK, Brazil, South Africa Preliminary data from phase 3 trials expected ‘soon’, said lead jab researcher  Developers say they hope to deliver the… Read More »